Nebenwirkungen · Perjeta
Perjeta 420 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-126844 · Präparat HOS-096317
* ADRs with a fatal outcome have been reported. ** For the overall treatment period across the 4 studies. The incidence of left ventricular dysfunction and cardiac failure congestive reflect the MedDRA Preferred Terms reported in the individual studies. ° Hypersensitivity/anaphylactic reaction is based on a group of terms. °° Infusion-related reaction (IRRs) includes a range of different terms within a time window, see “Description of selected adverse reactions” below. † ADRs reported in the post marketing setting-
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T17:02:00Z · SHA-256 6016d8c18bd6393fee3263a4c99284c28598b1dd932428fe0deafc6401ff5816 · Passage e0926e1950638f267ee0c904c532afa25207ca66137f0bbd4742cbf049b078ed · Zeichen 6098–6676 im Abschnitt